Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be
challenging in post transplantation management. The introduction of calcineurin inhibitors …

The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …

Solid organ transplant (SOT) recipients receive immunosuppressive drugs (ISDs) and are
susceptible to developing severe COVID-19. Here, we analyze the Spike-specific T-cell …

Adoptive immunotherapy with virus-specific cytotoxic T cells (VSTs) has evolved over the
last three decades as a strategy to rapidly restore virus-specific immunity to prevent or treat …

Hematopoietic stem cell transplantation (HSCT) results in profound immunosuppression for
the first few months after the procedure, requiring patients to be revaccinated against …

There is emerging evidence that T-cell immunity plays an important role in preventing
severe coronavirus disease 2019 (COVID-19) infection and disease and that cellular …

The coronavirus SARS-CoV-2 is the causative pathogen of the COVID-19 pandemic that has
been causing global upheaval since 2019. The widespread administration of vaccines has …

Background Post-transplant or hematological cancer patients have a higher risk of mortality
after infection with ancestral and early variants of severe acute respiratory syndrome (SARS) …

Introduction The immunogenicity and efficacy of COVID-19 vaccination varied by
demographic, including solid organ transplant recipients on immunosuppressive therapy …

During the first outbreak of an emergent virus, methods need to be developed to rapidly
establish suitable therapies for patients with high risk of severe disease caused by the …